Voting Rights and Shares Capital of the Company
Nanobiotix (NASDAQ:NBTX) has released its monthly update on voting rights and share capital as of August 31, 2025. The company reported 48,236,771 shares outstanding, with 50,337,954 theoretical voting rights and 50,315,836 exercisable voting rights.
This disclosure is made in compliance with French regulatory requirements, as the company is listed on both Euronext Paris and Nasdaq.
Nanobiotix (NASDAQ:NBTX) ha pubblicato l'aggiornamento mensile sui diritti di voto e sul capitale sociale al 31 agosto 2025. La società ha riportato 48.236.771 azioni in circolazione, con 50.337.954 diritti di voto teorici e 50.315.836 diritti di voto esercitabili.
Questa comunicazione viene resa in conformità ai requisiti normativi francesi, poiché la società è quotata sia su Euronext Paris sia sul Nasdaq.
Nanobiotix (NASDAQ:NBTX) ha publicado su actualización mensual sobre derechos de voto y capital social al 31 de agosto de 2025. La empresa informó 48,236,771 acciones en circulación, con 50,337,954 derechos de voto teóricos y 50,315,836 derechos de voto ejercitables.
Esta divulgación se realiza de conformidad con los requisitos regulatorios franceses, ya que la empresa cotiza tanto en Euronext Paris como en Nasdaq.
Nanobiotix(NASDAQ:NBTX)는 2025년 8월 31일 기준의 의결권 및 자본에 대한 월간 업데이트를 발표했습니다. 회사는 발행 주식수 48,236,771주, 이론상 의결권 50,337,954, 행사가 가능한 의결권 50,315,836를 보고했습니다.
이 공시는 프랑스 규제 요건에 따른 것으로, 회사가 유로넥스트 파리와 나스닥에 모두 상장되어 있기 때문입니다.
Nanobiotix (NASDAQ:NBTX) a publié sa mise à jour mensuelle sur les droits de vote et le capital social au 31 août 2025. La société a enregistré 48 236 771 actions en circulation, avec 50 337 954 droits de vote théoriques et 50 315 836 droits de vote exerçables.
Cette communication est effectuée conformément aux exigences réglementaires françaises, la société étant cotée à la fois sur Euronext Paris et sur Nasdaq.
Nanobiotix (NASDAQ:NBTX) hat sein monatliches Update zu Stimmrechten und Kapitalbestand per 31. August 2025 veröffentlicht. Das Unternehmen meldete 48.236.771 ausstehende Aktien, mit 50.337.954 theoretischen Stimmrechten und 50.315.836 ausübbaren Stimmrechten.
Diese Offenlegung erfolgt im Einklang mit französischen regulatorischen Anforderungen, da das Unternehmen sowohl an der Euronext Paris als auch an der Nasdaq notiert ist.
Nanobiotix (NASDAQ:NBTX) أصدرت تحديثها الشهري حول حقوق التصويت ورأس المال حتى 31 أغسطس 2025. أشارت الشركة إلى 48,236,771 سهماً قائماً، مع 50,337,954 حقاً تصويتياً نظرياً و 50,315,836 حق تصويت قابل للتفعيل.
يتم هذا الكشف امتثالاً للمتطلبات التنظيمية الفرنسية، حيث أن الشركة مدرجة في كل من بورصة يورونكس باريس وناسداك.
Nanobiotix (NASDAQ:NBTX) 已公布截至2025年8月31日的投票权及股本月度更新。公司披露了在外流通股数为48,236,771股，理论投票权为50,337,954，可行使投票权为50,315,836。
本披露符合法国监管要求，因为公司同时在巴黎泛欧交易所和纳斯达克上市。
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Sept. 12, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| August 31, 2025 | 48,236,771 | 50,337,954 | 50,315,836 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
__________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
| France –HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global –uncapped Becky Lauer +1 (646) 286-0057 |
Attachment
- 2025-09-12 -- NBTX -- Voting Rights & Share Capital -- FINAL
FAQ
What is the current number of outstanding shares for Nanobiotix (NBTX)?
How many voting rights does Nanobiotix (NBTX) have as of August 2025?
Where is Nanobiotix (NBTX) stock listed?
What is Nanobiotix's (NBTX) ISIN code?
